EBS Q3 2018 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

Q3 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$174M+16.2% YoY

Gross Profit

$67M38.8% margin

Operating Income

$21M12.3% margin

Net Income

$21M12.0% margin

EPS (Diluted)

$0.41

QoQ Revenue Growth

-21.2%

Cash Flow

Operating Cash Flow

$174M

Free Cash Flow

$148M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$207M

Stockholders' Equity

$967M

Cash & Equivalents

$339M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$174M	$149M	+16.2%
Gross Profit	$67M	$83M	-19.1%
Operating Income	$21M	$48M	-55.4%
Net Income	$21M	$34M	-37.7%